Stella+ - Integrating a HRT prescribing decision tool in primary care workflows

Stella - 将 HRT 处方决策工具集成到初级保健工作流程中

• 批准号: 10057458
• 金额: $ 41.24万
• 依托单位: VIRA HEALTH LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10057458
• 关键词: Stella+; Integrating; HRT; prescribing; decision

Vira is motivated to make lives happier, healthier and more productive for the 1bn women worldwide (13m UK) coping with menopause. 80%+ report symptoms interfere with daily life and 50% say it has made work difficult or untenable, with 900k UK women quitting jobs annually. Symptoms include physical (hot flushes, weight gain, loss of libido) and psychological (mood swings, difficulty concentrating, depression, anxiety). Menopause can have severe long-term health implications: issues affecting women in later life, including cardiovascular disease, diabetes, osteoporosis and dementia, can be triggered at menopause. Improving treatment for menopause is urgently needed if we are to tackle these early on.The current care model is broken, with <10% of UK women saying they are happy with the care they receive. Fixing the model is a key priority of the All-Party Parliamentary Group on Menopause, which sets out need for urgent help for women: boosting support in the workplace, training on symptoms for health workers, improving access to treatment, and checks for all women at 45\.To address this, Vira has devised its Stella platform:Our first product, _Stella_, is a personalised menopause treatment and coaching app for women, and is already transforming symptom management. It enables women to access support --individually or via B2B subscriptions made by their workplace -- including exercise and diets plans, information, online yoga classes, access to cognitive behaviour therapy, etc.This project addresses the specific problems of training health practitioners and improving access to treatment by delivering Stella+. Stella+ is a clinical assessment tool for menopause, designed to support GPs and allied health professionals in making better decisions about prescriptions of hormone replacement therapy (HRT), and to optimise treatment review processes, with better identification of treatment ineffectiveness, side and adverse effects. Stella+ will build upon our Class IIa algorithms for prescribing HRT.

Vira致力于为全球10亿（1300万英国）更年期女性提供更快乐、更健康、更高效的生活。超过80%的人报告症状干扰日常生活，50%的人表示这使工作变得困难或难以维持，每年有90万英国女性辞职。症状包括身体（潮热，体重增加，性欲丧失）和心理（情绪波动，难以集中注意力，抑郁，焦虑）。更年期可能对健康产生严重的长期影响：影响妇女晚年生活的问题，包括心血管疾病、糖尿病、骨质疏松症和痴呆症，都可能在更年期引发。如果我们要尽早解决这些问题，就迫切需要改善更年期的治疗。目前的护理模式已经被打破，<10%的英国女性表示她们对所接受的护理感到满意。修复这一模式是所有党派的更年期议会小组的一个关键优先事项，该小组提出了为妇女提供紧急帮助的需求：加强工作场所的支持，为卫生工作者提供症状培训，改善获得治疗的机会，并为所有45岁的妇女进行检查。它使妇女能够获得支持-单独或通过其工作场所的B2B订阅-包括锻炼和饮食计划、信息、在线瑜伽课程、获得认知行为治疗等。Stella+是一种更年期临床评估工具，旨在支持全科医生和专职医疗人员对激素替代疗法（HRT）处方做出更好的决策，并优化治疗审查流程，更好地识别治疗无效，副作用和不良反应。Stella+将建立在我们的IIa类算法基础上，用于处方HRT。